文献速递乳腺癌

CYP2D6基因型预测乳腺癌他莫昔芬停药与预后

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
PubMed 文献 · J Clin Oncol · 2019-12-04

该前瞻性-回顾性研究纳入2005-2012年确诊并接受他莫昔芬治疗的1309例乳腺癌患者,分析CYP2D6代谢型与停药及预后的关联。发现弱代谢者和超快代谢者6个月停药率分别为7.1%和18.8%,乳腺癌特异性死亡率呈U型关联,调整风险比分别为2.59和4.52(以正常代谢者为参照)。

要点

  • 弱代谢者和超快代谢者他莫昔芬6个月停药率分别为7.1%和18.8%。
  • CYP2D6代谢型与乳腺癌特异性死亡率呈U型关联。
  • 弱代谢者和超快代谢者预后较正常代谢者差,提示需个体化剂量。

核心结论

  • 接受标准剂量他莫昔芬的乳腺癌患者中,弱代谢者和超快代谢者较正常代谢者预后更差。

研究设计与样本

  • 前瞻性-回顾性研究,链接临床乳腺癌登记、瑞典处方药登记和自我报告问卷数据。
  • 对2005-2012年确诊并接受他莫昔芬治疗的1309例乳腺癌患者进行CYP2D6基因分型。
  • 将患者分为弱、中间、正常和超快代谢型,采用Cox回归分析代谢状态与停药及预后的关联。

主要发现

  • 弱、中间、正常和超快代谢者的他莫昔芬6个月停药率分别为7.1%、7.6%、6.7%和18.8%。
  • CYP2D6代谢状态与乳腺癌特异性死亡率呈U型关联。
  • 以正常代谢者为参照,弱代谢者调整风险比为2.59(95% CI 1.01-6.67),中间代谢者为1.48(95% CI 0.72-3.05),超快代谢者为4.52(95% CI 1.42-14.37)。

临床怎么用

  • 对接受他莫昔芬治疗的乳腺癌患者,可考虑CYP2D6基因分型以识别弱代谢者和超快代谢者。
  • 弱代谢者和超快代谢者预后较差,U型关联提示可能需要个体化他莫昔芬剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the association between CYP2D6 genotype, discontinuation of tamoxifen therapy, and prognosis for breast cancer. PATIENTS AND METHODS: We conducted a prospective-retrospective study linking data from a clinical breast cancer register, the Swedish Prescribed Drug Register, and self-reported questionnaires. We genotyped CYP2D6 in 1,309 patients with breast cancer who were treated with tamoxifen and were diagnosed from 2005 to 2012; they were categorized as poor, intermediate, normal, or ultrarapid CYP2D6 metabolizers. We investigated whether metabolizer status was associated with tamoxifen discontinuation and prognosis for breast cancer using Cox regression analysis. RESULTS: The 6-month discontinuation rates of tamoxifen among poor, intermediate, normal, and ultrarapid CYP2D6 metabolizers were 7.1%, 7.6%, 6.7%, and 18.8%, respectively. A U-shaped association was found between CYP2D6 metabolizer status and breast cancer-specific mortality, with adjusted hazard ratios of 2.59 (95% CI, 1.01 to 6.67) for poor, 1.48 (95% CI, 0.72 to 3.05) for intermediate, 1 (reference) for normal, and 4.52 (95% CI, 1.42 to 14.37) for ultrarapid CYP2D6 metabolizers. CONCLUSION: Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen. This U-shaped association might call for individualized tamoxifen dosage.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. He W, Grassmann F, Eriksson M, et al. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. J Clin Oncol. 2019. PMID: 31800347. doi:10.1200/JCO.19.01535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。